<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Between 1971 and 1990, nine patients ranging in age from 14-38 years received marrow transplants for <z:hpo ids='HP_0004818'>paroxysmal nocturnal hemoglobinuria</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Six were transplanted for aplastic complications of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Four of these were from HLA-identical siblings, and the patients were conditioned with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>One graft was form a syngeneic twin without conditioning, and one from a two HLA-antigen nonidentical father after conditioning with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> and total body irradiation </plain></SENT>
<SENT sid="4" pm="."><plain>Three of the four recipients of allogeneic marrow developed <z:hpo ids='HP_0011009'>acute</z:hpo> and two <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) </plain></SENT>
<SENT sid="5" pm="."><plain>Five of six transplanted for severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> are long-term survivors with follow-up ranging from more than 6.2 to more than 19.1 years </plain></SENT>
<SENT sid="6" pm="."><plain>The HLA nonidentical transplant recipient experienced graft rejection and died of a <z:mp ids='MP_0001182'>pulmonary hemorrhage</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>Three patients were transplanted for nonaplastic complications of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> consisting of life threatening recurrent thromboses or refractory <z:mp ids='MP_0010163'>hemolysis</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>Two of these patients received marrow grafts from HLA-identical siblings after conditioning with <z:chebi fb="0" ids="28901">busulfan</z:chebi> and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>They are surviving with <z:mpath ids='MPATH_458'>normal</z:mpath> hemograms greater than 2.2 and greater than 2.5 years and had mild <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD which resolved, although one has biochemical evidence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> in 15% of the red cells </plain></SENT>
<SENT sid="10" pm="."><plain>One received a syngeneic marrow graft without conditioning but reverted to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>He is alive greater than 8.6 years after transplantation </plain></SENT>
<SENT sid="12" pm="."><plain>Marrow transplantation for aplastic complications of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> is successful, well tolerated, and compatible with long-term survival when an HLA-identical sibling or a syngeneic donor is available </plain></SENT>
<SENT sid="13" pm="."><plain>For patients without <z:mpath ids='MPATH_58'>aplasia</z:mpath>, one must weigh the complications of transplantation with the life threatening nature of thrombotic episodes and <z:mp ids='MP_0010163'>hemolysis</z:mp> </plain></SENT>
</text></document>